Search Result
Results for "
superior
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B1035
-
|
l-Bunolol hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
Others
|
|
Levobunolol (l-Bunolol) hydrochloride is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol hydrochloride is an ocular hypotensive agent and lowers mean intraocular pressure (IOP). Levobunolol hydrochloride can be used for glaucoma and superior oblique myokymia (SOM) research .
|
-
-
- HY-W020983
-
|
Triflic acid silver; Perfluoromethanesulfonic acid silver; Fluorad FC 24 silver
|
Biochemical Assay Reagents
|
Others
|
|
Trifluoromethanesulfonic acid (Triflic acid) silver, a perfluoroalkanesulfonic acid, is one of the superior catalysts for C- or O-acylation .
|
-
-
- HY-18996
-
-
-
- HY-133018
-
|
|
HCV
|
Infection
|
|
HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC50s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity .
|
-
-
- HY-133018A
-
|
|
HCV
|
Cancer
|
|
HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC50s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 hydrochloride has anti-viral activity .
|
-
-
- HY-B1035A
-
|
l-Bunolol
|
Adrenergic Receptor
|
Others
|
|
Levobunolol (l-Bunolol) is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol is an ocular hypotensive agent and lowers mean intraocular pressure (IOP). Levobunolol can be used for glaucoma and superior oblique myokymia (SOM) research .
|
-
-
- HY-132925
-
|
|
Fungal
|
Infection
|
|
Antifungal agent 16 displays considerable antibacterial activity and superior antifungal activity with reference to ciprofloxacin and fluconazole, respectively.
|
-
-
- HY-157025
-
|
|
Herbicide
|
Others
|
|
Herbicidal agent 1 （(S)-6q）is a herbicidal agent with superior activity than its racemate .
|
-
-
- HY-112081A
-
|
|
DNA/RNA Synthesis
|
Others
|
|
BAY-707 acetate is a highly potent and selective substrate-competitive inhibitor of MTH1 with superior cellular target engagement and pharmacokinetic properties.
|
-
-
- HY-15402D
-
|
BMS 207940 hydrate
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
Edonentan (BMS 207940) hydrate is a potent and selective antagonist of the endothelin A (ETA) receptor, with a Ki of 10 pM. In rats, Edonentan has superior (100%) oral bioavailbility .
|
-
-
- HY-123214
-
|
|
Antibiotic
Bacterial
|
Others
|
|
Rifametane is a new 3-azamethyl-rifamycin with a pharmacokinetic profile superior to that of rifampin and activity with peak serum concentrations higher than that of rifampin in healthy volunteers.
|
-
-
- HY-162764
-
|
|
Androgen Receptor
|
Cancer
|
|
Androgen receptor degrader-5 (compound 14k) exhibits promising properties, including superior androgen receptor degradation activity and antiproliferative activity .
|
-
-
- HY-115568
-
|
|
PROTACs
Epigenetic Reader Domain
|
Cancer
|
|
BETd-246 is a second-generation and PROTAC-based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET, exhibiting superior selectivity, potency and antitumor activity .
|
-
-
- HY-119396
-
|
|
Endogenous Metabolite
|
Cancer
|
|
DY3002 is a selective and highly potent EGFR inhibitor with activity in overcoming T790M-mediated drug resistance in non-small cell lung cancer. DY3002 exhibited superior inhibitory effects against EGFR T790M mutants in kinase assays (IC50 = 0.71 nM), compared to weaker inhibitory effects against wild-type EGFR (IC50 = 448.7 nM). DY3002 was significantly superior to rociletinib and osimertinib in selectivity, showing an extremely high selectivity index (SI = 632.0). In cell experiments, DY3002 had an IC50 value of 0.037 μM against H1975 cells, showing enhanced inhibitory potency. In addition, DY3002 was superior to other alternative compounds in terms of biological properties and did not cause hyperglycemia .
|
-
-
- HY-B0380B
-
|
GIC-1001
|
Biochemical Assay Reagents
|
Others
|
|
Trimebutine 3-TCBS (GIC-1001) is an innovative formulation designed to release hydrogen sulfide (H2S) in vivo. This compound combines trimebutine with an H2S-releasing antagonist (phenyl 3-thiocarbamate) and exhibits enhanced anti-nociceptive effects in a mouse colonic distension model, superior to conventional trimebutine. GIC-1001 can reduce visceral pain and discomfort associated with lumen distension in a dose-dependent manner, showing potential superiority .
|
-
-
- HY-130511
-
|
|
Bacterial
|
Infection
|
|
FCE 22250 is a 3-azinomethylrifamycin with long-term in vivo persistence and good oral absorption. FCE 22250 shows superior efficacy against a broad antimicrobial spectrum including mycobacteria .
|
-
-
- HY-144773A
-
|
HR1405–01
|
COX
|
Inflammation/Immunology
|
|
Loxoprofenol-SRS tromethamine (HR1405-01), an active metabolite of Loxoprofen, is a Safe intravenous non-steroidal anti-inflammatory drug (NSAID) with superior anti-inflammatory and analgesic activities .
|
-
-
- HY-129059
-
|
NNC 756
|
Dopamine Receptor
|
Neurological Disease
|
|
Odapipam (NNC 756) is a selective, high affinity and benzazepine dopamine D1 receptor antagonist with a Kd of 0.18 nM. Odapipam is also a superior positron emission tomography (PET) radiotracer .
|
-
-
- HY-162030
-
-
-
- HY-121137
-
|
BocMPO
|
Biochemical Assay Reagents
|
Others
|
|
BMPO (BocMPO) is a cell-permeable superior spin trap with favorable chemical and spectroscopic features. BMPO (BocMPO) can be used for detecting thiyl radicals, hydroxyl radicals, superoxide anions and glutathiyl radicals .
|
-
-
- HY-131903
-
|
|
IRAK
|
Inflammation/Immunology
|
|
HS271 is a highly potent, orally active and selective IRAK4 inhibitor, with an IC50 of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic properties .
|
-
-
- HY-122050
-
|
|
Sodium Channel
|
Neurological Disease
|
|
Oe-9000 is a compound with local anesthetic activity that inhibits voltage-gated Na + currents in neurons, including both TTX-resistant and TTX-sensitive currents, with effects superior to those of some other local anesthetics.
|
-
-
- HY-151890
-
|
|
Fluorescent Dye
|
Cancer
|
|
NIR-βgal-2 is a β-galactosidase-activated near-infrared fluorescent probe with superior sensitivity. NIR-βgal-2 can be used for visualizing β-galactosidase in breast cancer .
|
-
-
- HY-13611
-
|
BN 80915
|
Topoisomerase
|
Cancer
|
|
Diflomotecan (BN 80915) is a potent and orally active inhibitor of topoisomerase I. Diflomotecan (BN 80915) causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds .
|
-
-
- HY-157014
-
|
|
Tryptophan Hydroxylase
|
Cancer
|
|
TPT-004 is a TPH inhibitor. TPT-004 has superior pharmacokinetic and pharmacodynamic properties. TPT-004 also has good efficacy in preclinical models of peripheral serotonin attenuation and colorectal tumor growth .
|
-
-
- HY-41189
-
|
|
ADC Linker
|
Cancer
|
|
Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers .
|
-
-
- HY-155361
-
|
|
PROTACs
|
Cancer
|
|
PROTAC BRD9 Degrader-7 is an orally active and selective degrader of BRD9 with a DC50 of 1.02 nM. PROTAC BRD9 Degrader-7 has superior oral activity with a Cmax of 3436.95 ng/mL .
|
-
-
- HY-151556
-
|
|
Fungal
|
Infection
|
|
Antifungal agent 45 is with fungicidal activities. Antifungal agent 45 shows excellent characteristics superior to Kresoxim-methyl (HY-125776), in which the activity enhancement against Phytophthora capsici was the most remarkable, with an EC50 value of about 5 μM .
|
-
-
- HY-125830
-
|
|
Biochemical Assay Reagents
|
Others
|
|
ITIC, non-fullerene acceptor, is an indacenodithienothiophene-based postfullerene electron acceptor, crystallizes in a profoundly different way as compared to fullerenes.
ITIC has a superior thermal stability and undergoes a glass-crystal transition considerably below its high Tg of 180 °C.
|
-
-
- HY-109023
-
|
|
Proton Pump
Na+/K+ ATPase
|
Others
|
|
Azeloprazole is a compound used to inhibit acid-related diseases. It is a proton pump inhibitor that inhibits H?,K?-ATPase in pig gastric vesicles. It can effectively inhibit gastric acid secretion in the dog's gastric fistula model. The effect is long-lasting and superior to esomeprazole.
|
-
-
- HY-163192
-
|
|
ROR
|
Cancer
|
|
W6134 is highly potent and selective RORγ covalent inhibitor with IC50 of 0.21 μM. W6134 exhibits superior activity ini nhibiting the proliferation and colony formation and inducing apoptosis. W6134 can be used for the research of cancer .
|
-
-
- HY-170480
-
|
SilMA (MW 100000)
|
Biochemical Assay Reagents
|
Others
|
|
Silk fibroin (MW 100000) (SilMA (MW 100000)) is a natural polymer composed of fibroin and sericin. Silk fibroin has demonstrated remarkable efficacy in spinal cord injury (SCI) reconstruction due to its superior biocompatibility, biodegradability, and tunable mechanical properties .
|
-
-
- HY-120391
-
|
|
Biochemical Assay Reagents
|
Others
|
|
LiLo is a new bifunctional chelator that has the activity of forming kinetically stable chelates with metal ions (such as indium). After using LiLo to bind indium-111 to monoclonal antibodies, the in vitro stability and in vivo biodistribution of the conjugates are superior to those using other chelators.
|
-
-
- HY-B1789
-
|
|
mAChR
|
Neurological Disease
|
|
Telenzepine is an antimuscarinic agent with Kis of 0.94 nM (M1 mAChR) and 17.8 nM (M2 mAChR) binding to muscarinic receptors. Telenzepine effectively blocks synaptic transmission promoted by muscarinic or M1 receptor agonists. Thus, Telenzepine can reduce the amplitude of extracellular slow excitatory postsynaptic potentials (EC50=38 nM) and slow inhibitory postsynaptic potentials (EC50=253 nM) .
|
-
-
- HY-N13182
-
|
|
Others
|
Others
|
|
Taxoquinone is an antioxidant derived from Metasequoia glyptostroboides and belongs to the diterpenoid class of compounds. At a concentration of 150 μg/mL, Taxoquinone exhibits a maximum inhibition of DPPH radicals of 81.29%, demonstrating superior antioxidant activity compared to Ascorbic acid and α-tocopherol at the same concentration .
|
-
-
- HY-128602
-
|
|
c-Kit
|
Cancer
|
|
c-Kit-IN-2 is a c-KIT inhibitor with an IC50 of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI50s of 3, 1, and 2 nM, respectively .
|
-
-
- HY-157930
-
|
|
Others
|
Cardiovascular Disease
|
|
TP-2, a caltrop-like multicationic small molecule, is an antidote that can completely neutralize both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs). TP-2 is not only superior to protamine, has higher neutralization activity, but is also biocompatible .
|
-
-
- HY-135368
-
8pyDTZ
3 Publications Verification
|
Fluorescent Dye
|
Others
|
|
8pyDTZ is a pyridyl diphenylterazine (DTZ) analog and an ATP-independent pyridyl substrate of LumiLuc luciferase. 8pyDTZ exhibits spectrally shifted emission. 8pyDTZ has excellent biocompatibility and superior in vivo sensitivity. 8pyDTZ can be used for in vivo luminescence imaging .
|
-
-
- HY-168122
-
|
|
Apoptosis
|
Cancer
|
|
Apoptosis inducer 29 (compund Y9) is an apoptosis inducer that exhibits antitumor effects in non-small cell lung cancer. Apoptosis inducer 29 selectively acidifies lysosomes and induces lysosomal dysfunction, with superior potency to Gboixn (HY-111651) in vitro and in vivo. .
|
-
-
- HY-119002
-
|
|
Antibiotic
|
Others
|
|
BO-1236 is a compound with antibacterial activity. It has strong activity against Gram-negative bacteria including Pseudomonas aeruginosa. It has shown activity superior to or equivalent to that of some commonly used antibiotics in in vitro and in vivo experiments, and has a certain stability against β-lactamase.
|
-
-
- HY-130116A
-
|
|
STING
|
Cancer
|
|
IACS-8779 disodium is a highly potent stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy. IACS-8779 disodium shows robust activation of the STING pathway in vitro and a superior systemic anti-tumor response in the B16 murine model of melanoma .
|
-
-
- HY-151555
-
|
|
Fungal
|
Infection
|
|
Antifungal agent 44 (compound 2A-5) is an antifungal agent, and shows excellent fungicidal activity superior to Kresoxim-methyl (HY-125776). Antifungal agent 44 shows fungicidal activity against Phytophthora capsici most remarkably, with an EC50 value of about 5 μM .
|
-
-
- HY-109706
-
|
|
Bacterial
Fungal
|
Infection
|
|
(Rac)-CPI-098 shows antibacterial activity. (Rac)-CPI-098 exhibits superior anti-fungal activity against Monascus ruber, better activity against Aspergillus fumigates, good activity against Aspergillus niger and Aspergillus parasites and moderate activity against Candida albicans .
|
-
-
- HY-157402
-
|
|
Topoisomerase
EGFR
|
Cancer
|
|
Topoisomerase II/EGFR-IN-1 is topoisomerase II/EGFR dual inhibitor. Topoisomerase II/EGFR-IN-1 has superior cytotoxic activity to MCF-7, A549 and HCT-116 cell lines, displays strong apoptotic activity and can be used for the research of cancer .
|
-
-
- HY-136557A
-
|
PAD2-IN-1 hydrochloride
|
Protein Arginine Deiminase
|
Inflammation/Immunology
Cancer
|
|
AFM32a (PAD2-IN-1) hydrochloride, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. AFM32a hydrochloride shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold) .
|
-
-
- HY-136557
-
|
PAD2-IN-1
|
Protein Arginine Deiminase
|
Inflammation/Immunology
Cancer
|
|
AFM32a (PAD2-IN-1), a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. AFM32a shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold) .
|
-
-
- HY-160142
-
|
|
Btk
|
Cancer
|
|
UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling. UBX-382 shows superior degradation activity for wild-type and mutant BTK proteins and shows anti-cancer activity in murine xenograft models of TMD-8 cells .
|
-
-
- HY-161749
-
|
|
PROTACs
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
PROTAC ALK degrader-1 (compound B1) is an ALK degrader based on PROTACs, with the DC50 of 26 nM in H3122 EML4-ALK. PROTAC ALK degrader-1 can be used to synthesis PROTAC ALK degrader-2 (HY-161750) with superior bioavailability .
|
-
-
- HY-162985
-
|
|
CDK
|
Cancer
|
|
JHD205 is a CDK4/6 inhibitor that induces apoptosis and DNA damage. JHD205 inhibits DNA repair by upregulating Caspase3 and p-H2AX. JHD205 has superior potency to Abemaciclib (HY-16297A) in a xenograft chick embryo breast cancer model. .
|
-
-
- HY-W179151
-
|
|
Dopamine Receptor
|
Inflammation/Immunology
|
|
N-Octanoyl dopamine is superior to dopamine in protecting graft contractile function when administered to the heart transplant recipients from brain-dead donors. N-Octanoyl dopamine inhibits cytokine production in activated T-cells and diminishes MHC-class-II expression as well as adhesion molecules in IFNγ-stimulated endothelial cells .
|
-
- HY-103247B
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
EMD-66684 potassium salt is a non-peptide angiotensin II receptor antagonist that demonstrates significant antihypertensive effects in spontaneously hypertensive rats. EMD-66684 potassium salt exhibits nanomolar affinity for angiotensin II receptors, comparable to losartan in potency. EMD-66684 potassium salt shows increased activity when modified with acetamides, leading to superior blood pressure reduction.
|
-
- HY-103586
-
|
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
|
GS-441524, predominant metabolite of Remdesivir and superior to Remdesivir against Covid-19 , shows comparable efficacy in cell-based models of primary human lung and cat cells infected with coronavirus. GS-441524 could strongly inhibits feline infectious peritonitis virus (FIPV), with an EC50 of 0.78 μM .
|
-
- HY-B1658
-
|
(R)-Frovatriptan; SB 209509; VML 251
|
5-HT Receptor
|
Neurological Disease
|
|
Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura .
|
-
- HY-120465
-
|
|
HIV
|
Infection
|
|
ZINC36617540 is a novel Nef protein inhibitor with anti-HIV activity. ZINC36617540 exhibits superior binding affinity by binding to Nef protein. ZINC36617540 shows a similar binding mode to the prototype molecule B9 in molecular docking. The mechanism of action of ZINC36617540 mainly depends on its hydrophobic and electrostatic interactions with Nef protein .
|
-
- HY-103586A
-
|
|
DNA/RNA Synthesis
SARS-CoV
|
Infection
|
|
GS-441524 hydrochloride, predominant metabolite of Remdesivir and superior to Remdesivir against Covid-19 , shows comparable efficacy in cell-based models of primary human lung and cat cells infected with coronavirus. GS-441524 hydrochloride could strongly inhibits feline infectious peritonitis virus (FIPV), with an EC50 of 0.78 μM .
|
-
- HY-115513
-
|
|
Endogenous Metabolite
|
Infection
|
|
Pitstop 1 is a small molecule inhibitor with endocytosis-inhibiting activity. Pitstop 1 blocks the interaction of chaperones with the Krasin terminal domain in cells, thereby affecting the function of Krasin. Pitstop 1 exhibits superior biological activity in significantly inhibiting the effects of Krasin. Pitstop 1 acts as a dose that inhibits the entry of viruses and pathogens into cells and modulates cell signaling .
|
-
- HY-145823
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-42 (Compound 17b) is a potent inhibitor of EGFR with single-digit nanomolar activity. EGFR-IN-42 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-42 retains both ER antagonist activity and EGFR inhibition. EGFR-IN-42 has superior anti-cancer activity .
|
-
- HY-145824
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-43 (Compound 17c) is a potent inhibitor of EGFR with single-digit nanomolar activity. EGFR-IN-43 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-43 retains both ER antagonist activity and EGFR inhibition. EGFR-IN-43 has superior anti-cancer activity .
|
-
- HY-161472
-
|
|
Aldose Reductase
|
Cancer
|
|
Aldose reductase-IN-7 (Compound 6k) targets Aldose reductase. Aldose reductase-IN-7 exhibits potent enzyme inhibitory activity (Ki = 0.186 ± 0.020 μM), showing superiority to Epalrestat (HY-66009), which is currently in clinical use. Aldose reductase-IN-7 is less cytotoxic and possesses potent anticancer activity .
|
-
- HY-155135
-
|
|
HPPD
|
Others
|
|
HPPD-IN-1 (compound II-3) is a HPPD inhibitor. HPPD-IN-1 shows inhibitory activity of Arabidopsis thaliana HPPD (AtHPPD) with an IC50 value of 0.248 μM, which was superior to that of mesotrione (HY-12853) (0.283 μM) in vitro. HPPD-IN-1 shows excellent herbicidal activity against broadleaf and monocotyledonous weeds .
|
-
- HY-120638
-
|
|
Topoisomerase
|
Cancer
|
|
BMS-250749 is a topoisomerase I (Top I) inhibitor of the fluoroglycosyl-3,9-difluoroindolecarbazole class. BMS-250749 exhibits potent cytotoxicity and selectivity, and shows curative antitumor activity against Lewis lung cancer. BMS-250749 exhibits broad-spectrum antitumor activity superior to CPT-11 in certain preclinical xenograft models. .
|
-
- HY-149957
-
|
|
Parasite
|
Infection
|
|
Antileishmanial agent-16 (compound 14c) is an anti-Leishmania agent. Antileishmanial agent-16 has superior anti-Leishmania major promastigotes activity (IC50 = 0.59 µM) and anti-Leishmania major amastigotes activity (IC50 = 0.81 µM). Antileishmanial agent-16 has good safety to mammalian cells (VERO cells) .
|
-
- HY-117135
-
|
|
Sodium Channel
Calcium Channel
PKC
|
Cardiovascular Disease
|
|
HNS-32 is a compound with antiarrhythmic and vasodilatory effects in canine hearts, showing superior protective effects against ischemic and reperfusion arrhythmias compared to an equivalent dose of Mexiletine hydrochloride (HY-A0093). Furthermore, HNS-32 exhibits significant negative chronotropic effects on mammalian ventricular myocardium, indicating its potential application value in the study of acute coronary syndrome .
|
-
- HY-129819
-
|
|
Bacterial
|
Infection
|
|
(Rac)-DNDI-8219 is an antituberculosis compound with potent anti-leishmanial activity. (Rac)-DNDI-8219 demonstrated superior efficacy in the Leishmania donovani mouse model. (Rac)-DNDI-8219 showed promising activity in the Leishmania infantum hamster model. (Rac)-DNDI-8219 candidate compound R-6 provided excellent oral efficacy in the same hamster model .
|
-
- HY-116765
-
|
|
Endogenous Metabolite
|
Neurological Disease
|
|
MAO-B-IN-35 is a potent, selective, reversible monoamine oxidase B (MAO-B) inhibitor with high inhibitory activity. MAO-B-IN-35 can exhibit high selectivity and potency at a small molecule scale. MAO-B-IN-35 is designed and synthesized so that it can be efficiently obtained during standard synthesis procedures and has superior physical and chemical properties .
|
-
- HY-168501
-
|
|
Others
|
Inflammation/Immunology
|
|
Neuroprotective Agent 6 (Compound Y12) is a neuroprotective agent with antioxidant activity. Neuroprotective Agent 6 demonstrates superior neuroprotective effects in both cellular models induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and animal models induced by transient middle cerebral artery occlusion (tMCAO). Additionally, Neuroprotective Agent 6 exhibits significant metal chelating activity towards Cu 2+ .
|
-
- HY-163084
-
|
|
Others
|
Cancer
|
|
HJ445A is a potent MYOF inhibitor and binds to the MYOF-C2D domain with a KD of 0.17 μM. HJ445A potently repressed the proliferation of gastric cancer cells with IC50 values of 0.16 and 0.14 μM in MGC803 and MKN45, respectively. HJ445A demonstrates superior antitumor efficacy in vivo and can be used for cancer research .
|
-
- HY-155682
-
|
|
Bacterial
|
Infection
|
|
Antibacterial agent 150 (compound 5g) is an antibacterial agent with potent antibacterial activity against both Gram-positive bacteria and Gram-negative bacteria (MIC values ranging from 1-32 μg/mL). Antibacterial agent 150 can increase survival rate of MRSA (Methicillin-resistant Staphylococcus aureus)-infected mice .
|
-
- HY-123319A
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Antofloxacin is a well tolerate, orally active and broad-spectrum 8-amino-fluoroquinolone with potent antibacterial activities. Antofloxacin shows superior antibacterial activity against gyrA mutation-positive H. pylori strains, especially in Asn87- mutated strains, compared to levofloxacin. Antofloxacin is a weak, reversible inhibitor of CYP1A2 for the research of infections caused by a diverse group of bacterial species .
|
-
- HY-123319
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Antofloxacin hydrochloride is a well tolerate, orally active and broad-spectrum 8-amino-fluoroquinolone with potent antibacterial activities. Antofloxacin hydrochloride shows superior antibacterial activity against gyrA mutation-positive H. pylori strains, especially in Asn87- mutated strains, compared to levofloxacin. Antofloxacin hydrochloride is a weak, reversible inhibitor of CYP1A2 for the research of infections caused by a diverse group of bacterial species .
|
-
- HY-169008
-
|
|
PROTACs
Acetyl-CoA Carboxylase
|
Infection
|
|
PROTAC ACC degrader-1 (Compound 9b) is a Acetyl-CoA Carboxylase degrader. PROTAC ACC degrader-1 exhibits superior potency against Aphis craccivora (IC50 = 107.8 μg/mL). (Structure Note: Pink, Target protein ligand (HY-169009); Blue, E3 ligand (HY-10984); Black, linker (HY-W007559) .
|
-
- HY-B0067B
-
|
(R)-SM-5887
|
Topoisomerase
|
Cancer
|
|
(R)-Amrubicin ((R)-SM-5887) is an anthracycline that effectively treats lung cancer by intercalating into DNA and inhibiting topoisomerase II activity, which consequently hampers DNA replication as well as RNA and protein synthesis, leading to cell growth inhibition and apoptosis. This compound exhibits superior anti-tumor efficacy compared to traditional anthracycline drugs while lacking the cumulative cardiac toxicity typically associated with this drug class.
|
-
- HY-161647
-
|
|
Reactive Oxygen Species
Apoptosis
Autophagy
Ferroptosis
|
Cancer
|
|
Antitumor agent-156 (Compound 20) causes DNA damage and mitochondrial dysfunction, promotes reactive oxygen species
generation, activates endoplasmic reticulum stress, and induce apoptosis, autophagy and ferroptosis. Antitumor agent-156 shows superior antitumor activity against cancer cells including Cisplatin (HY-17394) resistance cells. Antitumor agent-156 displayS good liver-targeting ability .
|
-
- HY-B1658S
-
|
(R)-Frovatriptan-d3 hydrochloride; SB 209509-d3 hydrochloride; VML 251-d3 hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
Frovatriptan-d3 (hydrochloride) is the deuterium labeled Frovatriptan[1]. Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura[2].
|
-
- HY-142533
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
HL-PEG2k is a second near-infrared Ru(II) polypyridyl complex. HL-PEG2k exhibits a wavelength bathochromic shift, enhanced photothermal conversion efficiency (41.77%), and an antineoplastic effect against glioma. HL-PEG2k displays a superior biocompatibility and thus can be a potential theranostic platform to combat the growth and recurrence of tumors .
|
-
- HY-162488
-
|
|
Fungal
|
Infection
|
|
Laccase-IN-3 (Compound 2b) is a laccase inhibitor (IC50 = 1.02= μM) with significant antifungal activity. Laccase-IN-3 shows superior inhibitory effect on Botryosphaeria dothidea (EC50 = 0.17 mg/L). Laccase-IN-3 effectively blocks the catalytic function of laccase by binding to its active center. Laccase-IN-3 also disrupts pathogen cell membrane integrity and increases ROS .
|
-
- HY-W014700
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Glycyl-L-glutamic acid is a neurotrophic factor (NF) in vivo, and exerts function of maintenance of AChE content and activity. Glycyl-L-glutamic acid doesn’t act directly on AChE synthesis, and may prevent preganglionic neuronal degeneration .
|
-
- HY-124144
-
|
|
Endogenous Metabolite
|
Cancer
|
|
MMV667492 is a potent Ezrin inhibitor with the activity to inhibit the invasion phenotype of osteosarcoma cells. MMV667492 exhibited potent anti-Ezrin activity in all biological assays and its compound properties were superior to NSC305787. MMV667492 was able to exhibit morphological defect phenotypes associated with Ezrin inhibition in zebrafish embryos. MMV667492 also showed the ability to inhibit the lung metastasis of osteosarcoma cells that highly expressed Ezrin .
|
-
- HY-159917
-
|
|
Tyrosinase
Microtubule/Tubulin
|
Inflammation/Immunology
|
|
PPL agonist-1 is a highly selective Periplakin (PPL) agonist that increases cAMP levels by regulating PPL, thereby enhancing MITF expression and promoting melanin synthesis. Furthermore, PPL agonist-1 facilitates melanin production by regulating tryptophan metabolism. Compared to Ruxolitinib (HY-50856), PPL agonist-1 demonstrates superior efficacy. PPL agonist-1 holds potential for research into vitiligo treatment .
|
-
- HY-111755
-
|
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders .
|
-
- HY-168113
-
|
|
Others
|
Cancer
|
|
Antiproliferative agent-60 (compound 8c) is a 11-Azaartemisinin derivative with superior anticancer activities. Antiproliferative agent-60 shows IC50 values of 7.7 μM, 42.5 μM, and 15.5 μM for epidermoid carcinoma (KB), HepG2, and A549 cells, respectively. Antiproliferative agent-60 exhibits significant tumor selectivity, up to 32-fold higher compared to Hek293 normal cells .
|
-
- HY-117287A
-
|
BMS-986165 hydrochloride
|
Interleukin Related
JAK
IFNAR
|
Inflammation/Immunology
|
|
Deucravacitinib hydrochloride (BMS-986165 hydrochloride) is a highly selective all-site inhibitor with potent inhibitory activity against TYK2. Deucravacitinib hydrochloride can effectively block IL-12, IL-23 and type I interferon signaling. Deucravacitinib hydrochloride demonstrates significant efficacy in preclinical models of inflammatory bowel disease. Deucravacitinib hydrochloride demonstrated superiority over placebo and apremilast on multiple efficacy endpoints in moderate to severe plaque psoriasis. Deucravacitinib hydrochloride was well tolerated in inhibition .
|
-
- HY-136576
-
|
|
LPL Receptor
Drug Metabolite
|
Inflammation/Immunology
|
|
RP101075, an active metabolite of Ozanimod, is a potent, orally active S1PR (sphingosine-1-phosphate receptor 1) agonist, with an EC50 of 0.27 nM. RP101075 displays >100-fold selectivity over S1PR5 (EC50=5.9 nM) and >10000-fold over S1PR 2, 3, and 4. RP101075 displays superior cardiovascular safety profile .
|
-
- HY-150109
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
Purinostat mesylate is a selective inhibitor of HDAC. Purinostat mesylate inhibits class I and class IIb HDACs with IC50s from 0.81 to 11.5 nM. Purinostat mesylate induces apoptosis and affects cell cycle of LAMA84 and 188 BL-2 cells, and shows potently anti-leukemia effects in vivo. Purinostat mesylate can be used for the research of lymphoblastic leukemia .
|
-
- HY-114778
-
|
SHR3162; Fuzuloparib
|
PARP
|
Cancer
|
|
Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC50=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .
|
-
- HY-114770
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
(E,E)-GLL398 is a selective estrogen receptor degrader with potent binding activity to ERα (IC50 = 1.14 nM). (E,E)-GLL398 can effectively degrade ERα in MCF-7 breast cancer cells (IC50 = 0.21 μM). The introduced boronic acid group of (E,E)-GLL398 gives it superior oral bioavailability, with an AUC of 36.9 μg·h/mL in rats, which is significantly higher than that of GW7604 .
|
-
- HY-19145
-
|
CI-992
|
Renin
|
Cancer
|
|
PD-134672 (CI-992) is a renin inhibitor containing a 2-amino-4-thiazolyl substituent. PD-134672 potently inhibits monkey renin in vitro and only weakly inhibits the related aspartic protease bovine feline hepsin D. The compound exhibits oral hypotensive activity in hyperreninemic normotensive monkeys. Based on its superior efficacy and long-lasting effects in vitro and in the normotensive macaque model, PD-134672 was selected for further evaluation in renal hypertensive monkeys.
|
-
- HY-115319
-
|
|
Ferroptosis
|
Inflammation/Immunology
|
|
CP-24879 (hydrochloride) is a potent, selective and combined delta5D/delta6D inhibitor. CP-24879 (hydrochloride) can significantly reduce intracellular lipid accumulation and inflammatory injury in hepatocytes. CP-24879 (hydrochloride) exhibits superior antisteatotic and anti-inflammatory actions in fat-1 and ω-3-treated hepatocytes, and can be used for non-alcoholic steatohepatitis research .
|
-
- HY-132307
-
|
|
Bcl-2 Family
Apoptosis
|
Cancer
|
|
Mcl-1 inhibitor 6 is an orally active, selective myeloid cell leukemia 1 (Mcl-1) protein inhibitor with a Kd of 0.23 nM and a Ki of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, Kd>10 μM). Mcl-1 inhibitor 6 is a potent antitumor agent .
|
-
- HY-124305
-
|
|
Endogenous Metabolite
|
Infection
|
|
ML395 is a potent and selective allosteric inhibitor of phospholipase D2 with antiviral activity. The cellular PLD1 IC50 value of ML395 exceeds 30,000 nM, while its cellular PLD2 IC50 value is 360 nM. ML395 shows excellent pharmacokinetic characteristics in vitro and physiochemical properties superior to other reported phospholipase inhibitors. ML395 shows interesting antiviral activity in cell-based assays against multiple influenza virus strains (H1, H3, H5, and H7) .
|
-
- HY-19895
-
|
|
Bacterial
|
Infection
|
|
DS-8587 is a new fluoroquinolone with significant antibacterial activity. The MIC value of DS-8587 against clinically isolated amoxicillin-resistant Bacillus strains is superior to ciprofloxacin and levofloxacin. The antibacterial activity of DS-8587 is less affected by adeA/adeB/adeC or abeM efflux pumps, and has more advantages than ciprofloxacin. DS-8587 has a lower single-step mutation frequency than ciprofloxacin. DS-8587 may be an effective drug for inhibiting amoxicillin-resistant Bacillus infections .
|
-
- HY-159915
-
|
|
Parasite
|
Infection
|
|
Se2h is a cruzain inhibitor that exhibits strong activity against the intracellular amastigotes of Trypanosoma cruzi (EC50 < 1 μM, SI > 10), with an inhibitory activity against cruzain of IC50 < 100 nM (SI > 5.55). Compared to Benznidazole (HY-B1548) and the cruzain inhibitor K777 (HY-119293), Se2h shows superior selectivity and inhibition, while its selenazole structure reduces selenium-related toxicity. Se2h exhibits antiparasitic activity and holds promise for research in Chagas disease .
|
-
- HY-15346
-
Copanlisib
Maximum Cited Publications
26 Publications Verification
BAY 80-6946
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
|
-
- HY-W709349
-
|
D 9998 hydrochloride
|
Potassium Channel
iGluR
|
Inflammation/Immunology
|
|
Flupirtine hydrochloride (D 9998 hydrochloride) is a selective neuropotassium channel opener with analgesic activity. Flupirtine hydrochloride is used to inhibit a variety of pain conditions, including chronic musculoskeletal pain, migraines, and neuralgia. Flupirtine hydrochloride has antidepressant and antioxidant properties and may increase the analgesic effect in combination therapy with morphine. Flupirtine hydrochloride relieves abnormally increased muscle tension and has a muscle relaxant effect. Flupirtine hydrochloride is clinically superior to other drugs, such as tramadol and pantoxan, plus its side effects are better tolerated. Flupirtine hydrochloride has a significant effect on inhibiting neural hyperexcitability and therefore exhibits inhibitory potential in various pain states .
|
-
- HY-15346A
-
|
BAY 80-6946 dihydrochloride
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .
|
-
- HY-159924
-
|
|
Opioid Receptor
|
Neurological Disease
|
|
DBPR116 is a prodrug of BPRMU191 (HY-159923) with blood-brain barrier penetration capability. DBPR116 significantly improves the delivery of centrally targeted drugs. In combination with the antagonist Naltrexone (HY-76711), DBPR116 demonstrated superior safety and analgesic efficacy compared to morphine in various in vivo pharmacological studies, including thermal pain models, cancer pain models, constipation, sedation, psychological dependence, heart rate, and respiratory frequency. As a prodrug strategy for peripheral administration, DBPR116 effectively alleviates pain while reducing adverse effects, showing potential as a safer opioid analgesic .
|
-
- HY-N8618
-
|
|
Others
|
Others
|
|
Erythro-guaiacylglycerol-β-O-4'-dihydroconiferyl alcohol was identified as one of the phenolic compounds isolated from Canadian maple syrup (MS-BuOH). It exhibited antioxidant properties along with other phenolic compounds and coumarins isolated from the syrup. These compounds showed varying degrees of antioxidant activity, with phenolic derivatives and coumarins showing superior activity, more so than lignans and flavonoids. This study marks the first time that 16 of the 23 phenolic compounds, including Erythro-guaiacylglycerol-β-O-4'-dihydroconiferyl alcohol, have been identified in maple syrup .
|
-
- HY-124322
-
|
|
Beta-secretase
|
Neurological Disease
Inflammation/Immunology
|
|
NB-360 is a potent, brain penetrable, and orally bioavailable dual BACE1/BACE2 inhibitor (IC50: mouse and human BACE1=5 nM; BACE2=6 nM). NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in amyloid precursor protein(APP) transgenic mice. NB-360 can completely block the progression of Aβ deposition in the brains of APP transgenic mice. NB-360 shows excellent selectivity over the related aspartyl proteases pepsin, cathepsin D and cathepsin E .
|
-
- HY-125387
-
|
|
Src
|
Inflammation/Immunology
|
|
TOP1210 is a narrow-spectrum tyrosine kinase inhibitor with potent inhibitory activity against P38α, Src, and Syk kinases. TOP1210 effectively reduced proinflammatory cytokines released by peripheral blood monocytes, primary macrophages, HT29 cells, inflammatory cells in ulcerative colitis (UC) biopsies, and myofibroblasts isolated from inflamed colonic UC mucosa. TOP1210 showed significant anti-inflammatory effects in cell experiments and UC biopsies, superior to some selective kinase inhibitors. The multi-kinase inhibition of TOP1210 provides the possibility of obtaining a wider range of therapeutic effects, especially in the regulation of autoimmune responses .
|
-
- HY-P99116
-
|
RG7716
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
|
-
- HY-15346R
-
|
|
PI3K
Apoptosis
|
Cancer
|
|
Copanlisib (Standard) is the analytical standard of Copanlisib. This product is intended for research and analytical applications. Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .
|
-
- HY-117807
-
|
|
Ras
Farnesyl Transferase
VEGFR
|
Cancer
|
|
A-176120 is a selective inhibitor of farnesyl transferase (IC50=1.2 nM) based on a farnesyl pyrophosphate (FPP) analog, with superior selectivity against GGTaseI (IC50=423 nM), GGTaseII (IC50=3000 nM), and SSase (IC50>10 μM). A-176120 inhibits ras processing in H-ras transformed NIH3T3 cells and HCT116 K-ras mutant cells (ED50=1.6 and 0.5 μM, respectively). A-176120 has antiangiogenic and antitumor activities in vivo and reduces capillary structure formation and VEGF secretion .
|
-
- HY-158226
-
|
ElaMA
|
Biochemical Assay Reagents
|
Others
|
Elastin Methacrylated (ElaMA) elastin recruits and modulates innate immune cells and accelerates angiogenesis at the wound site, thereby improving wound regeneration. Elastin Methacrylated attracts large numbers of neutrophils and primarily M2 macrophages to the wound and induces their penetration into the hydrogel. Elastin Methacrylated has excellent immunomodulatory effects, leading to superior angiogenesis, collagen deposition and dermal regeneration . Elastin Methacrylated needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc.
|
-
- HY-19633A
-
|
|
Endogenous Metabolite
|
Neurological Disease
|
|
CS-003 is a triple neurokinin receptor antagonist with activity in inhibiting neurokinin-related respiratory diseases. CS-003 exhibits high affinity for human neurokinin 1, 2 and 3 receptors, withKi values of 2.3 nM, 0.54 nM and 0.74 nM respectively. The Ki values of CS-003 on the guinea pig neurokinin receptor are 5.2 nM, 0.47 nM and 0.71 nM respectively, showing superior inhibitory effect. CS-003 significantly inhibits the formation of inositol phosphate involving substance P, neurokinin A and neurokinin B through competitive antagonism. CS-003 significantly inhibits citric acid-induced cough, and its effect is better than other selective neurokinin receptor antagonists .
|
-
- HY-119618
-
|
|
Endogenous Metabolite
|
Cancer
|
|
R1498 is a multi-target kinase inhibitor with anti-angiogenic and anti-proliferative activities. R1498 mainly targets targets such as Aurora kinase and VEGFR2, which are associated with tumor development. R1498 showed moderate in vitro growth inhibition in a variety of tumor cells, with IC50 values in the micromolar range. R1498 showed anti-tumor efficacy superior to sorafenib in a variety of gastric cancer and hepatocellular carcinoma xenograft models, with tumor growth inhibition rates exceeding 80%, and tumor shrinkage was observed in some models. R1498 showed a 10-30% tumor shrinkage rate in three xenograft models derived from human primary gastric cancer tumors, further demonstrating its inhibitory potential. R1498 effectively inhibited Aurora A activity in vivo and reduced tumor vascularization .
|
-
- HY-19500
-
|
|
COX
|
Others
|
|
SC-75416 is a selective cyclooxygenase-2 inhibitor. Its pharmacokinetic/pharmacodynamic (PK/PD) model was used for development and clinical trial simulation to design a study protocol to verify its analgesic effect in a post-oral surgery pain model. The simulation results showed that 360 mg of SC-75416 may provide better pain relief than 400 mg of ibuprofen. The actual clinical trial results confirmed this hypothesis, and 360 mg of SC-75416 was indeed superior to 400 mg of ibuprofen in pain relief. The PK/PD model of SC-75416 showed good predictive performance and successfully predicted its clinical effect. These research results show that SC-75416, as a new selective COX-2 inhibitor, has potential clinical application value in the management of post-oral surgery pain.
|
-
- HY-159922
-
|
|
Androgen Receptor
|
Cancer
|
|
AR antagonist 9 is an orally bioavailable selective androgen receptor (AR) antagonist that exerts anticancer effects by disrupting the dimerization of AR ligand-binding domains, showing potential for overcoming drug resistance in prostate cancer (PCa). Its AR antagonistic activity has an IC50 value of 0.051 μM, comparable to Enzalutamide (HY-70002) (IC50 = 0.060 μM). AR antagonist 9 demonstrated superior efficacy against ARF876L/T877A and ARW741C mutants compared to Enzalutamide (HY-70002). Furthermore, AR antagonist 9 exhibited favorable pharmacokinetic properties, with an oral bioavailability of F = 66.24% in rats. In the LNCaP xenograft mouse model, oral administration of AR antagonist 9 significantly inhibited tumor growth. AR antagonist 9 holds promise for research into overcoming PCa drug resistance .
|
-
-
-
HY-L198
-
|
|
117 compounds
|
|
Unlike the 20 natural amino acids commonly found within living organisms, non-natural amino acids are synthesized through chemical or biosynthetic methods, thereby being endowed with unique chemical properties or biological activities. In drug development, these amino acids can be utilized to design novel pharmaceutical molecules that may exhibit superior pharmacological characteristics, such as increased selectivity, improved pharmacokinetic profiles, or reduced toxicity. In biomedical research, uon-natural amino acids can act as biological markers or probes for investigating biological processes like cell signaling, protein conformation, and protein-protein interactions. In addition, non-natural amino acids can also be used in the field of agriculture to develop new pesticides, plant growth regulators and so on.
|
-
-
HY-L129
-
|
|
54 compounds
|
|
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.
MCE carefully prepared a unique collection of 54 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.
|
| Cat. No. |
Product Name |
Type |
-
- HY-151890
-
|
|
Fluorescent Dyes/Probes
|
|
NIR-βgal-2 is a β-galactosidase-activated near-infrared fluorescent probe with superior sensitivity. NIR-βgal-2 can be used for visualizing β-galactosidase in breast cancer .
|
| Cat. No. |
Product Name |
Type |
-
- HY-W020983
-
|
Triflic acid silver; Perfluoromethanesulfonic acid silver; Fluorad FC 24 silver
|
Biochemical Assay Reagents
|
|
Trifluoromethanesulfonic acid (Triflic acid) silver, a perfluoroalkanesulfonic acid, is one of the superior catalysts for C- or O-acylation .
|
-
- HY-158226
-
|
ElaMA
|
3D Bioprinting
|
Elastin Methacrylated (ElaMA) elastin recruits and modulates innate immune cells and accelerates angiogenesis at the wound site, thereby improving wound regeneration. Elastin Methacrylated attracts large numbers of neutrophils and primarily M2 macrophages to the wound and induces their penetration into the hydrogel. Elastin Methacrylated has excellent immunomodulatory effects, leading to superior angiogenesis, collagen deposition and dermal regeneration . Elastin Methacrylated needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc.
|
-
- HY-170480
-
|
SilMA (MW 100000)
|
3D Bioprinting
|
|
Silk fibroin (MW 100000) (SilMA (MW 100000)) is a natural polymer composed of fibroin and sericin. Silk fibroin has demonstrated remarkable efficacy in spinal cord injury (SCI) reconstruction due to its superior biocompatibility, biodegradability, and tunable mechanical properties .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-W014700
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Glycyl-L-glutamic acid is a neurotrophic factor (NF) in vivo, and exerts function of maintenance of AChE content and activity. Glycyl-L-glutamic acid doesn’t act directly on AChE synthesis, and may prevent preganglionic neuronal degeneration .
|
-
- HY-P10794
-
|
|
Peptides
|
Cancer
|
|
LH2 peptide is a pH-responsive cell-penetrating peptide dimer with the amino acid sequence LHHLCHLLHHLCHLAG. It can increase its uptake in tumor cells under weakly acidic conditions (such as the tumor microenvironment) through the protonation of histidine residues (pKa approximately 6). When conjugated with the anticancer drug Paclitaxel (HY-B0015), the PTX-LH2 conjugate showed superior tumor suppression effects compared to paclitaxel alone in a subcutaneous breast tumor model. The LH2 peptide holds potential as a drug delivery vehicle in cancer research .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99116
-
|
RG7716
|
VEGFR
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N13182
-
-
-
- HY-N8618
-
|
|
Structural Classification
Monophenols
Source classification
Sapindaceae
Phenols
Acer saccharum Marshall
Plants
|
Others
|
|
Erythro-guaiacylglycerol-β-O-4'-dihydroconiferyl alcohol was identified as one of the phenolic compounds isolated from Canadian maple syrup (MS-BuOH). It exhibited antioxidant properties along with other phenolic compounds and coumarins isolated from the syrup. These compounds showed varying degrees of antioxidant activity, with phenolic derivatives and coumarins showing superior activity, more so than lignans and flavonoids. This study marks the first time that 16 of the 23 phenolic compounds, including Erythro-guaiacylglycerol-β-O-4'-dihydroconiferyl alcohol, have been identified in maple syrup .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B1658S
-
|
|
|
Frovatriptan-d3 (hydrochloride) is the deuterium labeled Frovatriptan[1]. Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura[2].
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-125387
-
|
|
|
Alkynes
|
|
TOP1210 is a narrow-spectrum tyrosine kinase inhibitor with potent inhibitory activity against P38α, Src, and Syk kinases. TOP1210 effectively reduced proinflammatory cytokines released by peripheral blood monocytes, primary macrophages, HT29 cells, inflammatory cells in ulcerative colitis (UC) biopsies, and myofibroblasts isolated from inflamed colonic UC mucosa. TOP1210 showed significant anti-inflammatory effects in cell experiments and UC biopsies, superior to some selective kinase inhibitors. The multi-kinase inhibition of TOP1210 provides the possibility of obtaining a wider range of therapeutic effects, especially in the regulation of autoimmune responses .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
